Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials

ConclusionsIn patients with HFEM, treatment with galcanezumab (120  mg and 240 mg) significantly reduced migraine headache days/month, maintained remission status at subsequent months until the end of the study, and improved patients’ quality of life versus placebo.Trial registrationClinicalTrials.gov Identifier: EVOLVE-1,NCT02614183; EVOLVE-2,NCT02614196.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research